Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3054 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laing E

Authors: Laing E, Kiss N, Michael M, Krishnasamy M, Gough K,

Keywords: neuroendocrine, nutrition, malnutrition, weight change, symptoms,

#3050 Radioembolization for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis

Introduction: Neuroendocrine liver metastases are clinically challenging and often non-resectable due to their frequent disseminated distribution. Radioembolisation with yttrium-90 labelled microspheres represents an emerging modality for NELM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Clift A

Authors: Clift A, Frilling A, Braat A, Alsafi A, Wasan H,

Keywords: liver, metastases, radioembolization, yttrium, selective internal radiation therapy,

#2998 Inter- and Intrapatient Mean Absorbed Dose Variation and Simplification of Dosimetric Workflow after PRRT

Introduction: Post-PRRT dosimetry is not routinely performed, partly due to required multiple imaging time points. One time point imaging would reduce patient burden, and make dosimetry more applicable in the clinical settings.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Huizing D, Versleijen M, Martens E, Verheij M, Sinaasappel M,

Keywords: dosimetry, PRRT, simplification,

#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Cameselle-Garcia S, Sardo E, Landolfi S, Merino-Casabiel X, Sánchez J,

Keywords: Neuroendocrine Neoplasms, Inflammatory Biomarkers, Gastroenteropancreatic,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.